Introduction
============

Diabetic macular edema (DME) is a leading cause of visual loss in developed nations.[@b1-opth-11-2099],[@b2-opth-11-2099] A number of therapeutic approaches have been tested for refractory DME including focal macular photocoagulation and injections of intravitreal steroids or anti-endothelial growth factor (VEGF) agents, all with satisfactory outcomes.[@b3-opth-11-2099]--[@b6-opth-11-2099] Vitrectomy has also been tested but has had moderate outcomes and is controversial.[@b7-opth-11-2099] This surgical approach depends on the assumption that vitreous attachment may adversely affect the course of DME; therefore, relieving vitreomacular traction would be beneficial.[@b8-opth-11-2099] Vitrectomy increases the oxygen supply to the retina, thereby improving retinal ischemia, and removes inflammatory cells and cytokines residing in the preretinal space and reduces the VEGF concentrations in the vitreous cavity.[@b9-opth-11-2099]--[@b14-opth-11-2099] As vitreous viscosity is estimated to be 300--2,000 times greater than aqueous viscosity, the diffusion coefficient of intravitreal molecules should increase by a similar magnitude after vitrectomy.[@b15-opth-11-2099],[@b16-opth-11-2099]

However, some patients still experience recurrent DME even in the absence of vitreomacular traction or vitreous itself because of previous surgical interventions. As vitrectomy would not be effective for these patients, we hypothesized that a direct approach could be beneficial for resolving edema. This involves making an incision in the cyst, which contains dense inflammatory deposits, and cleaning it. This maneuver is delicate and could cause some complications such as retinal tears and macular holes, even though there are no neuronal components on the vitreous side of the macular cysts.[@b17-opth-11-2099] We were able to perform this technique safely using microscope-integrated intraoperative optical coherence tomography (iOCT). This recently introduced method is a novel imaging modality that provides dynamic feedback of tissue alterations during surgery and seamlessly integrates image acquisition, thereby allowing real-time assessment and safer delicate maneuvers.[@b18-opth-11-2099],[@b19-opth-11-2099]

Since there are not many reports describing surgical approaches other than vitrectomy for the treatment of refractory DME, we aimed to evaluate the outcomes of cystotomy for this condition under the guidance of iOCT.

Patients and methods
====================

In this observational case study, we retrospectively reviewed 20 eyes with a clinical diagnosis of diabetic retinopathy and refractory cystoid macular edema (CME). All patients had been diagnosed and treated at our institute. Written consent was given by patients for their information to be stored in the hospital database and used for research. This study was performed according to the tenets of the Declaration of Helsinki.

All patients underwent a standard three-port transconjunctival vitrectomy (25 gage or 27 gage) performed by the same surgeon (NT). Triamcinolone acetonide was intravitreously injected during vitrectomy to visualize the vitreous. The epiretinal membrane (ERM) was peeled in the macular region at the discretion of the surgeon. All concomitant internal limiting membrane (ILM) peeling was performed using diluted brilliant Blue G. After these procedures, the temporal margin of the cystoid space was vertically incised using a 27-gage needle, followed by an additional horizontal incision and flushing the cystoid space with 50--100 μL balanced salt solution (BSS). The surgical method for cystectomy is shown in [Figure 1](#f1-opth-11-2099){ref-type="fig"}. This maneuver is also shown in [Video S1](#SD1-opth-11-2099){ref-type="supplementary-material"}. Pars plana vitrectomy (PPV), release of vitreoretinal adhesion, ERM and ILM peeling and cystotomy were all performed under the guidance of iOCT (RESCAN 700; Carl Zeiss Meditec AG, Jena, Germany). Lensectomy and intraocular lens implantation were combined for removing significant cataracts that were present preoperatively or for anticipated postoperative cataract formation. This surgical procedure was performed by corneal 2.2 mm incision, phacoemulsification and aspiration of the cataract and in the bag implantation of a hydrophilic acrylic lens.

The Wilcoxon signed-rank test was used to compare the preoperative and 1- and 6-month postoperative measurements of central retinal thickness (CRT), central minimum macular thickness (CMMT), macular volume (MV) and best-corrected visual acuity (BCVA). CRT, CCMT and MV were evaluated using the Heidelberg Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany) in accordance with the manufacturer's instructions. BCVA was converted to the logarithm of the minimum angle of resolution (logMAR) for statistical analysis. All analyses were performed using the R statistical software (R version 3.1.3, released on 2015; R Foundation for Statistical Computing, Vienna, Austria).

Ethics
------

The research ethics committee of Shinseikai Toyama Hospital approved this study.

Results
=======

The characteristics of patients are presented in [Table 1](#t1-opth-11-2099){ref-type="table"}. There were six females and 14 males, with a mean age of 64.1±8.2 years. The mean follow-up period was 10.8±3.6 months. Preoperatively, nine eyes were pseudophakic and 11 were phakic. All patients underwent release of vitreoretinal adhesion, ERM and ILM peeling and cystotomy. Of these, 11 patients with phakic eyes also underwent PPV, phacoemulsification and aspiration (PPV triple + cystotomy group). Six of the nine patients with pseudophakic eyes underwent combined cystotomy with PPV only (PPV + cystotomy group), and the remaining three patients, who had avitreous eyes, did not undergo any additional procedures (cystotomy only group).

At the 6-month postoperative follow-up, six patients in the PPV triple + cystotomy group needed additional treatment, including intravitreal or sub-Tenon's capsule injection of corticosteroids. Two patients in the PPV + cystotomy group required additional treatment. No intra- or postoperative complications such as macular hole or retinal tear were observed in any of the 20 patients.

The preoperative mean CRT of 461±75 μm, which was significantly decreased to 385±42 μm (*P*\<0.01) 1 month after surgery and to 391±84 μm (*P*\<0.01) 6 months after surgery. There were not significant changes between results at 1 month after surgery and 6 months after surgery ([Figure 2](#f2-opth-11-2099){ref-type="fig"}). The preoperative CMMT of 392±77 μm also significantly decreased to 265±80 μm (*P*\<0.01) 1 month after surgery and to 268±91 μm (*P*\<0.01) 6 months after surgery. There were not significant changes between results at 1 month after surgery and 6 months after surgery ([Figure 3](#f3-opth-11-2099){ref-type="fig"}). These significant reductions between preoperative and 6 months after surgery in CRT and CMMV were only seen in the PPV + cystotomy group (*P*\<0.05). The preoperative MV of 10.8±1.4 mm^3^ was significantly reduced to 10.3±1.0 mm^3^ (*P*\<0.01) 1 month after surgery and to 9.7±1.0 mm^3^ (*P*\<0.01) 6 months after surgery. Significant reductions were also seen between results at the 1-month and 6-month follow-ups (*P*\<0.01; [Figure 4](#f4-opth-11-2099){ref-type="fig"}). There was not a significant improvement between the preoperative BCVA (0.43±0.31) or 1-month postoperative BCVA (0.30±0.25). However, there was a significant improvement between the preoperative and 6-month postoperative (0.25±0.23) BCVA measurements (*P*\<0.01). This improvement was measured in 13 eyes (65%) only. There were no changes in five eyes (25%), and two eyes (10%) presented deterioration ([Figure 5](#f5-opth-11-2099){ref-type="fig"}).

Discussion
==========

This study shows that cystotomy is an option for the resolution of refractory CME. Although this maneuver is delicate and can potentially cause macular holes or retinal tears, we were able to perform this technique safely under the guidance of iOCT without any serious intraocular complications. The fact that there are no neuronal components on the vitreous side of the macular cysts[@b17-opth-11-2099] is also an advantage for this technique.

One of the causes of DME is vascular leakage to the retina. This is due to increased vascular permeability, which is caused when the blood--retinal barrier breaks down, and increased numbers of inflammatory cytokines. When dense fluid composed of deposits such as lipoproteins remains in the fovea, the osmotic gradient presumably becomes higher. This hampers fluid drainage by the retinal pigment epithelium and consequently worsens the macular edema. The postoperative photoreceptor status of the fovea and the integrity of the external limiting membrane and the ellipsoid zone on optical coherence tomography (OCT) are positively correlated with visual acuity in eyes with resolved DME after vitrectomy.[@b20-opth-11-2099]--[@b22-opth-11-2099] Since chronic DME causes permanent photoreceptor dysfunction and disrupts the integrity of the external limiting membrane and the ellipsoid zone, early resolution of DME is crucial. In the clinical real-life, there are some cases of DME in which resolution cannot be achieved with repeated conventional treatment.

In this study, we chose cases that were resistant to conventional treatments such as photocoagulation, corticosteroids and anti-VEGF injection. We managed to resolve macular edema and improve visual acuity, which suggests that our novel technique improves CME pathology by a different mechanism to that used by conventional medical treatments. Possible explanations for the effectiveness of our treatment include injecting BSS into the cystoid space to wash out deposits and cytokines in the fovea, thereby reducing the oncotic pressure and facilitating drainage from the retina to the choroid. Our intraoperative findings also supported this explanation: dense liquids were found floating from the intraretinal space while flushing the cystoid space with BSS. We also noticed a capsule in some cases, which presumably contained dense fluid composed of inflammatory deposits ([Figure 1C](#f1-opth-11-2099){ref-type="fig"}).

It is also notable that, with the exception of two eyes (patients 11 and 14; [Table 1](#t1-opth-11-2099){ref-type="table"}), the beneficial effects on macular edema continued for 6 months with only a few additional treatments required. In some cases, a dramatic improvement in visual acuity and macular edema was achieved, which was still observed 6 months after surgery ([Figure 6](#f6-opth-11-2099){ref-type="fig"}). This long-term effect could be a benefit of the direct cleaning of dense fluid and cytokines. This not only reduces leakage from the retinal vessels but also allows time for the retina to reattach with the choroid, thereby enabling the choroid to resume supplying nutrients and oxygen to the retina.

A recent meta-analysis showed that vitrectomy produces structural and functional improvements in selected eyes with DME, but the visual gains were not significantly better than those achieved with laser or in an observation group.[@b7-opth-11-2099] In this era where several medical treatments are available, including anti-VEGF agents, it is clear that surgery would not be the first choice of treatment. However, there are always some cases that are resistant to these conventional treatments. Favorable results have been obtained using additional surgical approaches for DME other than vitrectomy. Avci et al[@b23-opth-11-2099] excised plaque-like foveal hard exudates from 11 patients with chronic DME and reported a significant long-term improvement in BCVA (logMAR) at the 3-year follow-up. Morizane et al treated diffuse DME in 20 patients using a planned foveal detachment technique. This involved injecting 50--100 μL BSS into the subretinal space using a 38-gage needle. Significant improvements in CRT and BCVA were seen after 6 months in 13 eyes (65%). Six (30%) eyes remained unchanged, and one (5%) eye worsened.[@b24-opth-11-2099] Similarly, we found a significant decrease in CRT 6 months after surgery. Improvements in BCVA were also seen 6 months after surgery in 13 (65%) eyes. Five (25%) eyes remained unchanged, and two (5%) eyes worsened. Our results are similar to those of prior studies, indicating that the technique that we performed would also be an option for refractory CME.

Limitations of our study include its retrospective nature; therefore, the details of the surgical procedures, follow-up protocols and treatment histories before surgery were not standardized. Moreover, the number of eyes in the cystotomy only group was small compared to those in the other two groups that underwent combined procedures. Further large-scale prospective controlled studies are warranted to validate our findings.
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![Surgical method for cystotomy for refractory DME.\
**Notes:** After core vitrectomy and removal of the ILM, the temporal margin of the cystoid space was vertically incised using a 27-gage needle (**A**), followed by an additional horizontal incision (**B**) and flushing the subfovea with 50--100 μL BSS. The arrow indicates the capsule that floated out from the retina while flushing BSS into the fovea, assumedly containing subretinal fluid (**C**). Resolution of CME was achieved (**D**). The magnification of images is ×25.\
**Abbreviations:** DME, diabetic macular edema; ILM, internal limiting membrane; BSS, balanced salt solution; CME, cystoid macular edema.](opth-11-2099Fig1){#f1-opth-11-2099}

![Changes in the CRT before surgery and 1 month and 6 months after surgery.\
**Note:** The bars and the asterisk indicate significant changes between two periods (*P*\<0.01).\
**Abbreviation:** CRT, central retinal thickness.](opth-11-2099Fig2){#f2-opth-11-2099}

![Changes in the CMMT before surgery and 1 month and 6 months after surgery.\
**Note:** The bars and the asterisk indicate significant changes between two periods (*P*\<0.01).\
**Abbreviation:** CMMT, central minimum macular thickness.](opth-11-2099Fig3){#f3-opth-11-2099}

![Changes in the MV before surgery and 1 month and 6 months after surgery.\
**Note:** The bars and the asterisk indicate significant changes between two periods (*P*\<0.01).\
**Abbreviation:** MV, macular volume.](opth-11-2099Fig4){#f4-opth-11-2099}

![Preoperative and postoperative BCVA of 20 eyes that underwent cystotomy for refractory DME.\
**Note:** Only 19 eyes are presented on the scatterplot because two eyes had a preoperative and postoperative BCVA of 0.398.\
**Abbreviations:** BCVA, best-corrected visual acuity; DME, diabetic macular edema; logMAR, logarithm of the minimum angle of resolution; PPV, pars plana vitrectomy.](opth-11-2099Fig5){#f5-opth-11-2099}

![Spectral-domain OCT results of cystotomy in patient 20.\
**Notes:** Patient 20 was a 66-year-old female diagnosed with diabetes mellitus at 60 years of age. She developed recurrent macular edema after panretinal photocoagulation even after seven anti-VEGF intravitreal injections and six sub-Tenon's capsule injections of corticosteroids. (**A**) Before surgery, showing apparent cystic macular edema. The CRT was 555 μm, and BCVA (logMAR) was 0.301. (**B**) Two days after surgery, showing successful incision of the foveal cyst. (**C**) One month after surgery, showing the foveal contour gradually recovering. (**D**) Six months after surgery, showing complete regression of CME. The CRT was 385 μm, and BCVA (logMAR) was 0.000. (**E**) An intraoperative OCT image showing the fovea after incision of the cyst.\
**Abbreviations:** OCT, optical coherence tomography; CRT, central retinal thickness; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; CME, cystoid macular edema.](opth-11-2099Fig6){#f6-opth-11-2099}

###### 

Characteristics of patients undergoing cystotomy for refractory diabetic macula edema

  No   Sex   Age (years)   Follow-up (months)   Lens status    Vitreous status   Intervention             BCVA (logMAR)   CRT     CMMT   MV    Additional treatment (no of treatments)                         
  ---- ----- ------------- -------------------- -------------- ----------------- ------------------------ --------------- ------- ------ ----- ----------------------------------------- ----- ------- ------- -----------------
  1    F     52            10                   Pseudophakic   Vitreous          PPV + cystotomy          0.222           0.155   597    423   566                                       270   12.72   10.50   None
  2    F     52            10                   Pseudophakic   Vitreous          PPV + cystotomy          1.000           0.301   656    460   579                                       353   12.2    10.34   None
  3    M     68            13                   Pseudophakic   Vitreous          PPV + cystotomy          0.523           0.523   410    272   324                                       210   11.34   10.59   IVTA1
  4    M     68            13                   Pseudophakic   Vitreous          PPV + cystotomy          0.222           0.222   456    376   434                                       249   11.28   10.19   IVTA1
  5    M     67            13                   Pseudophakic   Vitreous          PPV + cystotomy          0.398           0.398   387    308   340                                       111   7.67    6.56    None
  6    F     78            22                   Pseudophakic   Vitreous          PPV + cystotomy          0.155           0.097   403    332   367                                       259   9.43    8.59    None
  7    M     54            9                    Pseudophakic   Avitreous         Cystotomy                0.398           0.398   426    335   395                                       191   11.17   9.75    None
  8    M     54            9                    Pseudophakic   Avitreous         Cystotomy                0.398           0.301   422    378   387                                       235   10.88   10.10   None
  9    M     75            7                    Pseudophakic   Avitreous         Cystotomy                0.301           0.046   484    344   363                                       74    9.27    8.95    None
  10   F     72            7                    Phakic         Vitreous          PPV triple + cystotomy   0.824           0.222   470    440   369                                       397   ND      10.65   None
  11   M     68            7                    Phakic         Vitreous          PPV triple + cystotomy   0.046           0.155   346    347   265                                       303   9.53    8.48    None
  12   M     67            7                    Phakic         Vitreous          PPV triple + cystotomy   0.523           0.222   419    422   370                                       355   9.96    9.02    None
  13   F     56            10                   Phakic         Vitreous          PPV triple + cystotomy   0.222           0.000   450    407   424                                       362   11.37   10.46   None
  14   M     73            10                   Phakic         Vitreous          PPV triple + cystotomy   0.222           0.301   387    453   354                                       404   11.8    9.90    None
  15   M     70            9                    Phakic         Vitreous          PPV triple + cystotomy   0.097           0.097   484    487   421                                       371   10.41   9.77    IVTA1
  16   M     65            9                    Phakic         Vitreous          PPV triple + cystotomy   1.155           1.000   451    655   392                                       326   13.83   10.81   IVTA1
  17   M     55            10                   Phakic         Vitreous          PPV triple + cystotomy   0.824           0.301   485    330   330                                       197   11.18   9.82    STTA1 and IVTA1
  18   M     55            11                   Phakic         Vitreous          PPV triple + cystotomy   0.155           0.046   513    331   390                                       245   10.77   10.33   STTA1 and IVTA1
  19   M     66            14                   Phakic         Vitreous          PPV triple + cystotomy   0.699           0.301   412    341   307                                       239   10.16   10.11   STTA1 and IVTA1
  20   F     66            15                   Phakic         Vitreous          PPV triple + cystotomy   0.301           0.000   555    385   458                                       207   10.27   9.53    STTA1

**Abbreviations:** BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; CRT, central retinal thickness; CMMT, central minimum macular thickness; MV, macular volume; F, female; PPV, pars plana vitrectomy; M, male; IVTA1, single intravitreal injection of triamcinolone acetonide; STTA1, single sub-Tenon's capsule injection of triamcinolone acetonide.
